The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Open accessAbstract
Galectin-3 is a β-galactoside-binding lectin which is important in numerous biological activities in various organs, including cell proliferation, apoptotic regulation, inflammation, fibrosis, and host defense. Galectin-3 is predominantly located in the cytoplasm and expressed on the cell surface, and then often secreted into biological fluids, like serum and urine. It is also released from injured cells and inflammatory cells under various pathological conditions. Many studies have revealed that galectin-3 plays an important role as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease, viral infection, autoimmune disease, neurodegenerative disorders, and tumor formation. In particular, it has been recognized that galectin-3 is extremely useful for detecting many of these diseases in their early stages. The purpose of this article is to review and summarize the recent literature focusing on the biomarker characteristics and long-term outcome predictions of galectin-3, in not only patients with various types of diseases, but associated animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Galectins: A family of animal β-galactoside-binding lectins
Barondes, S. H., Castronovo, V., Cooper, D. N. W., Cummings, R. D., Drickamer, K., Felzi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., Kasai, K.-I., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90498-7 · Cited by 1,223
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562 · cited 2×
“Absence of Gal-3 protected against activated myofibroblast accumulation and fibrosis in experimental hydronephrosis mouse model induced by unilateral ureteric obstruction [87].”
BackgroundVlassara, H., Li, Y. M., Imani, F., Wojciechowicz, D., Yang, Z., Liu, F.-T., & Cerami, A. (1995) · Molecular Medicine · doi:10.1007/bf03401604 · Cited by 421
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0610-4 · Cited by 211
Rotshenker, S. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9186-7 · Cited by 111 · cited 3×
“Gal-3 is a unique marker of activated resident microglial and recruited macrophages from blood circulation [42].”
BackgroundInfluential
Cited by
The therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02469-6 · Cited by 66
“Interestingly, Gal-3 has been detected in the CSF of AD patients and its measures suggest that it could be elevated in AD [21, 59].”
Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases
Tian, Y.-K., Ye, D.-W., Ge, M.-M., Chen, N., Zhou, Y.-Q., & Yang, H. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201094547 · Cited by 31
Akkaya, H. Ü., Yılmaz, H. E., Narin, F., & Sağlam, M. (2022) · Journal of Periodontology · doi:10.1002/jper.21-0137 · Cited by 25
Metadata
- Authors
- Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., & Tomita, H.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2020-03-03
- Volume
- 10
- Issue
- 3
- Pages
- 389
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W3010158051
- Cited by
- 214
- References
- 8
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. https://app.cochat.ai/papers/10.3390/biom10030389
- The paper
- Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., & Tomita, H. (2020). Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. https://doi.org/10.3390/biom10030389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.